Future Innovations in Oncology : Update Bulletin # 3 [April 2019]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in future innovations in oncology, including: ImmunoGen announcing that their Phase II FORWARD I trial failed to meet its primary endpoint of progression-free survival (PFS); Novocure announcing initiation of their pivotal Phase III INNOVATE-3 trial to test the efficacy of tumour treating fields (TTFs) combined with paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC); and Seattle Genetics/Genmab A/S announcing the completion of enrolment in the potentially pivotal InnovaTV 204 Phase II study for tisotumab vedotin.

Business Questions:

• What is viewed as the reason behind the failure of FORWARD I to reach its primary endpoint?
• How do experts see the future of mirvetuximab soravtansine in ovarian cancer treatment?
• Is the folate receptor a viable target for ovarian cancer therapy?
• How do the KOLs view TTFs in their ability to effectively treat ovarian cancer?
• Are the experts optimistic that Novocure's INNOVATE-3 trial will have a positive outcome?
• If approved, where are TTFs anticipated to be positioned within the ovarian cancer treatment algorithm?
• What do experts think of the potentially pivotal InnovaTV 204 study?
• Should InnovaTV 204 have a positive outcome, does an opportunity exist for tisotumab vedotin to impact the CVC market?
• What aspects could hinder tisotumab vedotin future CVC market share?